Strides Pharma Science Limited (BOM:532531)
India flag India · Delayed Price · Currency is INR
992.05
+35.05 (3.66%)
At close: Aug 20, 2026

Strides Pharma Science Cash Flow Statement

Millions INR. Fiscal year is Apr - Mar.

Operating Activities

Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Net Income
5,56235,935-706.12-2,026-4,602
Depreciation & Amortization
1,9421,8542,1232,3012,162
Other Amortization
81.5368.683.99131.21168.49
Loss (Gain) From Sale of Assets
-1,042-40.95-14.32-41.0741.9
Asset Writedown & Restructuring Costs
-0.450.051,575330.41,774
Loss (Gain) From Sale of Investments
--1,021--656.07-558.62
Loss (Gain) on Equity Investments
-4.69-18.371,7572,8531,108
Stock-Based Compensation
3.1416.0915.8613.01-7.09
Provision & Write-off of Bad Debts
-63.0910.85175.67344.171.78
Other Operating Activities
1,551-28,2242,8091,773-767.15
Change in Accounts Receivable
-1,093-516.33390.9-3,474-587.95
Change in Inventory
-3,018-2,269307.04-81.38281.86
Change in Accounts Payable
3,1071,049-1,485-1,023-1,593
Operating Cash Flow
7,0256,8447,011444.11-2,578
Operating Cash Flow Growth
2.65%-2.38%1478.58%--

Investing Activities

Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Capital Expenditures
-4,179-2,475-1,182-949.38-1,434
Sale of Property, Plant & Equipment
63.9681.03888.0672.58753.74
Cash Acquisitions
-217.74-78.77-58.78--2,195
Divestitures
513.69-66.695,193-
Sale (Purchase) of Real Estate
1,07950---
Investment in Securities
845.53331.75-765.96-1,5611,569
Other Investing Activities
164.91154.4490.69269.64118.67
Investing Cash Flow
-1,730-896.89-1,5033,025-1,187

Financing Activities

Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Short-Term Debt Issued
--2,424-4,564
Long-Term Debt Issued
1,7051,7141,0733,3044,507
Total Debt Issued
1,7051,7143,4983,3049,071
Short-Term Debt Repaid
-1,308-2,030--504.55-
Long-Term Debt Repaid
-2,793-3,444-7,901-3,081-3,132
Total Debt Repaid
-4,101-5,475-7,901-3,586-3,132
Net Debt Issued (Repaid)
-2,396-3,761-4,403-281.825,939
Issuance of Common Stock
3.8661.0213.7413.6736.18
Common Dividends Paid
-368.65-229.9-135.17--224.31
Other Financing Activities
-1,773-2,496-2,409-1,871-1,538
Financing Cash Flow
-4,534-6,426-6,933-2,1394,213

Net Cash Flow

Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Foreign Exchange Rate Adjustments
0.58-5.381.621.461.28
Miscellaneous Cash Flow Adjustments
--0.22-1.35-3.39-
Net Cash Flow
761.32-484.56-1,4251,328448.96

Free Cash Flow

Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Free Cash Flow
2,8464,3695,829-505.27-4,012
Free Cash Flow Growth
-34.86%-25.05%---
Free Cash Flow Margin
5.86%9.57%14.98%-1.37%-13.07%
Free Cash Flow Per Share
30.8847.4864.06-5.61-44.70
Levered Free Cash Flow
-44.062,0581,8532,939-8,600
Unlevered Free Cash Flow
893.743,3543,3434,299-7,689

Additional Metrics

Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Cash Interest Paid
1,7732,4962,9222,2421,538
Cash Income Tax Paid
711.12-670.39-242.47-876.45-23.28
Change in Working Capital
-1,004-1,736-787.32-4,578-1,899